Holen Sie sich die Stockscreener-App
28.50
1.33%
0.375
Handel nachbörslich:
28.45
-0.045
-0.16%
Schlusskurs vom Vortag:
$28.12
Offen:
$28.38
24-Stunden-Volumen:
5,454
Relative Volume:
0.98
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.05%
1M Leistung:
+1.84%
6M Leistung:
-2.85%
1J Leistung:
-18.21%
1-Tages-Spanne:
$28.32
$28.50
1-Wochen-Bereich:
$28.12
$28.82
52-Wochen-Spanne:
$25.32
$35.59
Tema Heart Health Etf Stock (HRTS) Company Profile
Firmenname
Tema Heart Health Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie HRTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTS
Tema Heart Health Etf
|
28.50 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
309.80 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
628.86 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
631.74 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
244.81 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
561.25 | 124.43B | 0 | 0 | 0 | 0.00 |
Tema Heart Health Etf Aktie (HRTS) Neueste Nachrichten
5 Small-cap Biotech ETFs to Watch - Investing News Network
Short Interest in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Declines By 28.6% - Defense World
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Short Interest Down 60.0% in February - Defense World
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs - ETF Trends
Why the Rich World Is Going to Need AI and Africa - Bloomberg
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends - ETF Trends
Tema's New VOLT ETF Sparked by AI Revolution - etf.com
Disruptive Theme of the Week: Happy Post-Election Themes - ETF Trends
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win - Nasdaq
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Nasdaq
Tap the Weight-Loss Drug Market With These ETFs - Nasdaq
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says - CNBC
Disruptive Theme of the Week: The Rise of Active Thematic ETFs - ETF Trends
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment - Yahoo Finance
ETF Innovators: 11 people disrupting the industry, creating unique products, and delivering mammoth returns - Business Insider
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO - markets.businessinsider.com
This ETF is trying to satisfy appetites for weight loss stocks - CNBC
ETF IQ: Mutual Fund Managers Have the Luxury to Just Say ‘No’ - Bloomberg
Investing in the diabesity epidemic: a breakthrough moment | Opto - CMC Markets
OZEM, Weight Loss Drug ETFs: Should You Invest? - etf.com
Obesity Market to Reach $150B as Demand Grows, Supply Stabilizes: Reuters - BioSpace
Weight-loss drug forecasts jump to $150 billion as supply grows - Reuters
Play These New ETFs to Tap Lucrative Weight Loss Drug Market - Yahoo Finance
Another thematic ETF launches to target global obesity battle - InvestmentNews
Fighting Obesity Using ETFs - ETF Trends
S&P 500: April Selloff Could Be a Very Good Thing for the Months Ahead - Investing.com India
IBD Stock Of The Day Pops After Obesity Drug Crushes Sales Views - Investor's Business Daily
What Is a Healthcare ETF? Everything You Need to Know - ETF.com
The 5 Best Biotech ETFs of 2024 - etf.com
This weight-loss ETF has performed well. Here’s a look at other options. - MarketWatch
Is the global battle against obesity an opportunity for investors? - InvestmentNews
First Weight Loss ETF from Tema ETFs Announces Name Change, Tops $50 Million AUM - Markets Insider
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss - Investor's Business Daily
Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering - Value The Markets
LLY Stock: Study Highlights Weight Regain Risk with Lilly's Zepbound - Value The Markets
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund - Reuters
Finanzdaten der Tema Heart Health Etf-Aktie (HRTS)
Es liegen keine Finanzdaten für Tema Heart Health Etf (HRTS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
0.60%
Kapitalisierung:
|
Volumen (24h):